CB Insights April 6, 2021
Deepashri Varadharajan

In the past year, nearly 5,000 clinical trials were launched to test life-saving treatments and vaccines for the novel coronavirus.

Covid-19 clinical trial enrollment is 80% higher than average. However, this is less impressive when considering that for many diseases, such as cancer, less than 10% of eligible patients enroll in a trial. 

Patients often only enroll in a drug trial when existing forms of treatments have already failed. On top of that, not all diagnosed patients are eligible to participate — determining eligibility alone can be a herculean task.

For those that are eligible, participating in a trial is often a cost- and time-intensive endeavor. The process is inefficient for other stakeholders too: drug trials average nearly a decade, costing...

Topics: AI (Artificial Intelligence), Biotechnology, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Public Health, Technology
Spurred by the pandemic, AI is driving decentralized clinical trials
5 AI lessons from pharma world learned during Covid-19
Machine Learning Identifies Existing Drugs to Treat COVID-19
MIT researchers use AI to find drugs that could be repurposed for COVID-19
AI’s infiltration of pharma: How COVID-19 accelerated change

Today's Sponsors

Teladoc Health

Today's Sponsors

Canton & Company

Today's Sponsor